Genmab is squaring off with Janssen in a legal battle over royalties from the multiple myeloma drug Darzalex, and shares of the Denmark-based company fell in trading after the announcement.
https://www.pharmalive.com/wp-content/uploads/2020/09/Genmab-and-Janssen-Head-to-Arbitration-Table-Over-Darzalex-Royalties-BioSpace-9-23-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2020-09-23 12:08:272020-09-23 12:28:43Genmab and Janssen Head to Arbitration Table Over Darzalex Royalties